Document k9Bq4JkvZovJwpNLK6B3JqXDV

AR ARG -- IKE FLUOROCSHTEAMTUISCALRSEVIIENWBLOOD : =s/22719, BG e ooJnrognaMgnaciyhca3i0f,niup1o9er7ro8fc,laurob3roMonsinsifunorrfbmal:codeo-dDauctoifPvoeentmmpalotfoeyrefieiasnldsie.nxgpsosoefdantoic : lfaloiutaohdroilrdneeevmebillssowtosdeolrervdeuelsst.sof--ag1ensteowrsia7tt1oehpdop-cpmwewreiearrteaie-oifntnos-u-rnewadhn.eodgrfee"Hioher 4f8lu-o8r1ipnpem,in h3uMmarnesporitssaptphaatrenstomley tnorramcael,levie.el. oflesosrgatnhiacn 1 ppm. o Du Pont Program and Status Item : . status o Communication . 1. oIfnfo3rMmianffofremcatteidonC..W. employees Complete 6/27/78 e Toxicity 1. THeasstksellfor10M-PDDa-y50S0u4bac(uhtoemoFleogeding Complete : mciaxrtbuorxeylaotfesa)m;monpieurmflpueorrfolaulokryolalkyl m"eTtehfalcorn"ylaCtSeFsCa(rZp7Me,t TPLrFo-t1e8c3t7o)r; A(lTcLoFh-o4l1,13-TDL)F;-18Z4o7n)y;l BZAomy(lTeFlSoCmer B Z(oTnLyFl-3F63S5DC)(;TLZFo-m3y1l76)FS;N_ Zo(nTyLlF-T47e1l4aC): (Tclomer A, TLF 4187). 2. Analysis of rat blood o Medical Program 1. Rienvdiueswtriaalll chuyrgrieennte ocpoenrtartoilosnstoand _eixnpsousreuretshataretheprpopoetrelnytiaclosntrfoolrled. DZoonneylfoFrSNraatnsd fZeodny BA. Complete : "2. vIodrekntiofryhaavlel ewmorpkleodyeejsobwshoincwuhrircehntly Complete there is or was potential for IN exposure to fluorochemicals. z 3. Rseuvchiepwertshoensmedsitcialll reemcpolrodysedofbyall Complete 2& DuunusPounatl, helaolotkhingoccfuorrrecnocnessistorenttreonrds. EID08027L . \ , 000143 status 4. Oonbtpaeirnsbolnosodwhoflhuaovreochneemviecralhadlevels ptootefnltuioarlochfeormicoaclcsupattoioensatlableixsphosure background levels for a baseline. 5. oOnbtarienprbelsoeondtatfilvueoreomcphleomyieceasl wlietvhels various potentials for exposures to various fluorochemicals. Complete Complete for 55 c 199 employees. 6. Rtehveiweowrktehrespheyxsaimcianledfifnodrincgosnsiofstent or unusual health occurrences or trends. Complete 7. hIafstbheeenperoifodsuofffipcioetnetntidaulrateixopnosure To be decided eanmdplotyheeerse, isanaepsiudfefmiicoileongticnumsbteurdyof oifdetnhteifmioerdtamlaiytybeofcontshiedecroehdo.rt A dleitkeerlmihionoadtioofn chaanvinbeg made of the. a meaningful . setxupdoysedafteemrplothyeeesnumibserdetoefrmpirneevdi.ously e Program Cost to Date Total $149,400 1. Toxicity Testing MMRR--33018897 _ 2177,,400000 Total 44,400 2. B(lAododditAinoanlaylsibslood analysis, ~$500 each) $105,000 Z5g EID080272 - \ 000144 CHAMBERS WORKS FLUOROCHEMICALS I BLOOD STUDY (1) RESULTS OF STUDY = LEVELS OF FLUORINE IN THE BLOOD OF CHAMBERS WORKS EMPLOYEES, (INORGANIC AND LOW VOLATILITY ORGANIC FLUORINE) (2) INDUSTRIAL HYSIENE SURVEY + MANUFACTURE OF TELOMER B ALCOHOL ' MANUFACTURE OF ZEPEL FLUOROMONOMER, ZonvLe FSH, RP, FSE, FSP, UR . Ru D. RICHARDSON/AMB 18 May 1978 | o . X ' 000145\ 2 a EID080273 ORGANIC FLUORINE IN BLOOD GROUP (SAMPLE SIZE) 34 Data GENERAL POPULATION (106) PLANT OFFICE WORKER PLANT WORKER = GENERAL PLANT WORKER = LONG : SERVICE IN F/C AREA NEWER PLANT OLDER PLANT Du Pont DatA WILMINGTON CONTROL GROUP (25) Campers Horks Group (55) ppm ORGANIC FLUORINE 0,002 70 9,13 , 0.021** 0.01 0 0.06 0.13 70 1.18 : 0.9 70 9.1 5971071 ' 23 0F 25) 0-038 0.034) | (54 oF 55) 0 = 0.37 **** 0.15] . CONCLUSIONS : @ CamBERS HORKS EMPLOYEES DO NOT HAVE ELEVATED LEVELS OF ORGANIC FLUORINE IN THEIR BLOOD AS WAS REPORTED FOR 3M WORKERS. THE MEAN VALUE FOR CHAMBERS WORKS EMPLOYEES WAS SLIGHTLY HIGHER THAN THE NILMINGTON CONTROL GRoup [0,15 versus 0,034], BUT ALL VALUES ARE CONSIDERED TO BE "NORMAL" (<1 PPM) EXCEPT ONE VALUE IN THE WILMINGTON CONTROL GROUP (10.6 pm). * BY DIFFERENCE BETWEEN TOTAL AND INORGANIC FLUORINE ** [MeDIAN VALUES] *** except 2 VALUES 10.6; 0.78 % exer gycep1r VALUE 0,83 PPM & EID080274 . : 000146 CHAMBERS WORKS FLUOROCHEMICALS COHORT CHAMBERS WORKS EMPLOYEES WERE IDENTIFIED WHO (1) HAVE HAD JOB ASSIGNMENTS WITH POTENTIAL FOR EXPOSURE (2) ARE STILL ACTIVE OR ARE READILY AVAILABLE ON SITE BLOOD SAMPLES TAKEN AT REGULARLY SCHEDULED PHYSICAL EXAMINATION Jos ASSIGNMENT : LocAT1ON NuMBER NuMBER CHECKED IDENTIFIED To Date" 2) R&D Jackson Lag, 50 18 36) TecHNICAL LAB. DEVELOPMENT Spec. CHEM, 36 6 an MANUFACTURING WEST MANUFACTURING SPEC. CHEM. 84 26 GL East OTHER 29 5 an 199 55 8) . @ INFORMAL CHECK WITH SUPERVISION INDICATED THAT croup (55) SAMPLED WAS REPRESENTATIVE OF COHORT (199). g EID080275 . ' 000147' ' CONCLUSIONS - INDUSTRIAL HYGIENE SURVEY A) TewoMer B AucotoL AnD ZFM MANUFACTURE 1) ENVIRONMENTAL MONITORING DATA SUGGESTED CONDITIONS IN THE MANUFACTURING FACILITIES TO BE NORMALLY <5 Me/M3 TBA (8 HRs.) HOWEVER, EXCURSIONS TO RAISE THIS LEVEL TO 30 To 40 Me/M3 TBA (3 HRS.) HAVE BEEN OBSERVED ON MULTIPLE OCCASIONS, 2) ADDITIONAL ENVIRONMENTAL MONITORING REQUIRED TO IDENTIFY ' EXPOSURE SOURCES AND DEFINE POTENTIAL EXPOSURE LEVELS. (In PROGRESS) : 3) MOST PROBABLE EXPOSURE SOURCES ARE DRUMMING ANMD-DEBRUMMING FACILITIES, AND TO A LESSER EXTENT SAMPLING EQUIPMENT AND PROCEDURES+ 4) DRUMMING, DEDRUMMING AND SAMPLING FACILITIES ARE OF A LOW STANDARD FOR CONTAINMENT BY ENGINEERING CONTROLS, (oT ENCLOSED, NO LOCAL VENTILATION) 5) A CONTRIBUTING FACTOR IS THAT THE FACILITIES ARE ENCLOSED : IN A BUILDING, PROMPT ELIMINATION OF PROCESS LEAKS AND - MAINTAINENCE OF VENTILATION IS ESSENTIAL. B) Teromer B Arcono Use Areas LIMITED, AVAILABLE, ENVIRONMENTAL DATA SUGGEST THE . POTENTIAL FOR EXPOSURE TO TBA (anp Zonvie FSH) To BE LOH. 5 ' } ooptas FRU : RECOMMENDATIONS 1) DISCONTINUE PROGRAM TO DETERMINE FLUORINE IN BLOOD, . 2) ADVISE EMPLOYEES THAT BLOOD ANALYSIS PROGRAM HAS BEEN DIS- CONTINUED DUE TO UNIFORMLY FAVORABLE RESULTS. 3)" UPGRADE FACILITIES, IF REQUIRED, TO MEET HASKELL LABORATORY EXPOSURE LIMIT GUIDELINES WHEN THESE ISSUE. 18 May 1979 . g2 5 . 000149 [EID080282 e-- w . B 4 : Hi Portb 33 ES2B!4 o. rs LI = 2>I 12 - o - 4 PI t odt o aa 3 LI i a 1ge.od0 onFi 1 Big 2 sieb Ei dRdElUiegdlb:, dble ul abialiar slE sf. REERBfRf F onHi 2 3I if if ei gli b Co bhe fhoo ob EERE EE BIRT SgaEm, pLPofEoayonfosr oowpkr oFf hBE Dima EG an tie Hon sgoin oRdgd L :3 i s ss 0s 300% $i i BE PEE; rig 2s i 4 Hy pmo fy : 3jp s137 17 %8 21 zouiai :11=z i fLsE:E ) fei [A ob HY Pp op iFiElE op orrdcoLdER: 2iHh id E EDN Peed i i ) ~ ~ } 000150 EID080283 J . ORGANIC FLUOROCOMPOUNDS IN BLOOD - In May, 1978, fluorocompounds in 3M informed Du Pont of findings of organic blood of employees exposed to long-chai.n * perfluoro-surface active materials. 3M reported airborne contaminant levels up to 81 ppm in their operations and organic fluorine blood levels of 1 to 71 ppm for exposed workers. in humans 3M is reports normal, that i.e. some level of organic equal to or less than fluorine 1 ppm. Chambers Works makes. functional equivalents to the 3M fluorosurfactants and plant employees were findings in June 1978. Also a program was informed of the 3M initiated to define exposure potential in the Chambers Works fluorocompound manufacturing and use operations, review the medical records of employees assigned to these operations, determine organic fluorine levels in the blood of such employees and to gather additional toxicity information on selected plant fluorocompounds. Program results are summarized below: . . - By Bp > 725 PP~ - Airborne contaminant monitoring results show that the highest potential for employee fluorocompound exposure to be in the manufacturing facilities. Bight hour time weighted average measuremgnts ranged from <0.3 ppm (5 mg/m3) to 2 ppm (40 mg/m'). The drumming, dedrumming and sampling operations are major contributors to exposures above 0.3 ppm. Engineering control programs to reduce contaminant emissions from these sources is underway. Blood samples were taken from a representative sample of exposed employees and analyzed for organic fluorine. The mean organic fluorine value for Chambers Works employees was slightly higher than the Wilmington control group (0.15 ppm versus 0.094 ppm) but all values for exposed employees were less than . 1 ppm. This program has been discontinued. e A review and comparison of the medical records of active fluorocompound exposed plant employees with . a control group showed no adverse health effects. However, while the difference is not statistically significant, the number of employees with abnormal liver function tests was notably higher in the exposed group (6 compared to 1). Medical surveillance will be continued with study update December, 1979. Z5z : g ! & 000151 'EID080284 .p . /- 10-day subacute feeding tests carried out by Haskell tshhroeweedofcomthpeouenidghrtelaftleudoroncoonm-proeuvnedrssibtleesteedf.fects for . Nionn-rraetsverfseidbl4e,47l0ivmegr/kagn/ddatyestZeosnylefFfSeNctsanwder8e50nmogt/edkg/day + Zfeodnyl5,B0A0.0 mgD/eckrge/adsaeydZsonpyelrmTpelrao.ductTiheonnweaesd ffoorundfurinthrearts toxicity testing is being studied. Aofmteheetinrgesuilstsbeionfgouarrraprnoggerdamt.hrough Haskell Laboratory to inform 3M < i : = 3 . EID080285 000152 to ;me @UPONIDS fi Same E. I. ou PoNT bE NEMOURS 5 COMPANY. sna `WILMINGTON, DELAWARE 19898 CHEMICALS, DYESAND PIGMENTSDEPARTMENT BS.e FBs..! A. . ao:W. Wo Cm.e MwcuKyuwsick PJW..ellMK,aarrarEhsR,cDiaE,RDCW MD.adeS,hepFh&eFrd, PPs 3S.ereRnabientezs,, EPlPaEsR. LePERSONAL & a CONFIDENTIAL TO: MEETING ATTENDEES FROM: P. G. GILBY June 20, 1979 "%pryorocrEmIcaLs IN BLOOD 5/22/79 MEETING SUMMARY reachTehdisin ltehtetersubisjectto mseuemtmianrgi.ze dIitscwausssiaognrseedandthadte:cisions Item : Responsible for Coordination The Chambers Works program to --- determine organic fluorine blood levels will be discontinued. Chambers Works employees will be informed of the results and discontinuance of the blood analysis program. R. Richardson WFiollmlionwgutpownilclonbteroldongerouipn the employee whose blood sample was Dsra.mplJ.e Ch.asBonnonwetbteen(asdudbimtiitotneadl bfol: analysis) analyzed at 10.6 ppm organic fluorine. Medical records review study of Chambers Works exposed and R. Richardson to submit updated tabulation to P. G. Gilby for control group will be updated December 1979. Update will transmission to Dr. S. Pell. baebnolrimmailtedlivtoertafbuunlcattiioonntoesfts. . . EID080267 - : 000153 Item Responsible for Coordination : e Bfloroodempalnoayleyessishwaivlilngbepotdeonnteial R. M. Shepherd, PP&R WfaosrhienxgpotsounreWortkos.3M'sPP&FRC-w1i4l3l at tsoubGm.itH.saPmaptlteesrswoene,k of 6/18/79 CDP, Jackson Laboratory for analysis. EtongirendeuecreinTgelcoomnetrrolB Aprlocgorhaomls dauirribnogrnedrucmomnitnagm,indaentdrulmevmeilnsg aanndd psraomjpelcitnsg wiinlitliabteedd.efined R. Richardson . Accocnetpatmaibnlaentaierxbpoorsnuere limits qrueecsotmemdendfaotrioTneslowmielrlBbAelcroeh-ol T(eZloan)ylaBndA),ZEMT.elomer A (Zonyl Ws.ubmDiatrtneedll6/(1R2e/q7u9e)st to Haskell T(h1)e nfeuerdt,heriftoanxyi,citfyortesting o(f2) sMeSlDeScterdevifsliuoonrsochaenmdicals, w(i3)ll cbuestdoemteerrmnionteidf.ications R. E. Read wAitmheet3iMngtowirlelviebew DsuetPounpt tionxfiocrimtayt,ionb.lood and health Ft.hrEo.ugFhreB.ncMhcKwuislilckc,oorHdaisnkaetlel Discussion Summary rtHeeapssotkirentlgsl. fcoorOmfpltethehteedemiag1th0et-rdiafayllusosruobtacechstueetmdei,caflcesoemdpisonuugbnmdittetsretedslabtaeynddCDni&osPns-ufeodr Br4Ae,.v47e0rsDimebgcl/rekegal/sideadvyesrpZeo--nraymnlpdrF_oStdNuecastntidoe~ns8--5w0aesfmfgf/eoKucgnt/dndsoai_tynew-dTreeaxitlensomefrreadts(Zfoneydl) 5,000 mg/kg/day Zonyl Tela. kTnhoewmnedtiocahlaverecpoortdesntioafl22f1oracftliuvoeroCchhaemmbiecrasl Wococrukpsateimopnlaolyees z5 Tehxeposcuornetrowleregroruepvie(w2e21d aemnpdlocyoemepsa)rewdastoraandcoomntlryolseglreocutpe.d a wafhnridolmeA.CSht.ahDme.bedrisNfofWeoarrdekvnsecreseemisphlneooyateletshstaeafntfdiesmctatitsccahwleelrdyeassniogtnteoidf.iscexa,nHtoawge(vePer,0.05), Cwtaohsnetinnnuoumtebadebrlysoufhrivegehmieplrllaonyiceneesthisewiwteahxrpraoabsnnetoderdmg.arloupliv(e6rcofmupnacrteiodntotes1t).s . : 000154 EID080268 ' " : OBfloothdesaCmhpalmebsersweWreorktsakeenxpofsreodm fluorine. Du Pont Wilmington garorueppraensdentaantailvyezedsamfoprleor(g5a5)nic employees (25) having no |l`apmsoeattnehnevtailcauolentfrfooorlr fCglrhuoaoumrpboecrhtsoemWieocsratklasbolciecmsuphploabytaeiseoesnalwlianseexpslelovisegulhrste.lywerhTehieghuesred etfxlhcuaeonrpittnheoe)n,ecob1n0ut.rt6olapllgprmvoauvlpauleu(se0.a1f5roeunvdceornsiunssidteh0er.e0Wd9i4ltmpoipbnmegtoornngoarnmciaoclntr(oSl1 ppm) Wtgorarokukepsn. aemnApdloasyneeaceloysnzdeidbs.lnoooAtddwdsaiartmripaolnneatlefdrbolimonotvdhiiseawnaiolnyfdsiitvshiedoufalloCwwhivaalmlblueerbsse found. oAfunltu.oirnodcFuhlseutmoriiracolaclhehmmyaignciuaeflnaecetxsupuorrsivunergyeaopfnodtseuenslteeicaftlaecdwialCsihtaimfeboseurnwsdasWtoorckbaesr.ried h8loehwr.miannTWutAfh.aectuHusoerwienfvgaecrif,laictilileeivset.lisesAuiwprebrtooernn4e0ormmcgao/lnmlt>yami(5n2a.mn1gt/pmpl3mg)v,e(l0s.26inppm), ds8oonuherr.cetsoTWabAreewtetrederrumdmmeeifanisgnu,ereddeexdparonusdmurmaeidndgisotuairnocdneasls.ammpolMnioinstgtoropiprneogrbaaitbsiloebnesienxgposure vc(eofnnattciailmlaiitntiaionents.s)arfeErnongmiontteheenrsoiewngoepneccrloaontstireoodlnsanpdraorgehraavbmeesinngotodlerovecdeaullcoepeexdahiaraubnsodtrne projects will be initiated to improve these facilities. Ws3aaMsm'hpslienFsgCt-1of2no3rWofarnlkausloyrso(isPsuP.r&Rf)a.cTteaxtnPitPlReiswFiiulbsleerdssautbhamviSetprenumoaptnlceoyyete(eTFr)belaocaohndded > 2thedierciospieornatoinonwsh.ether or not blood analysis is warranted for For additional information, see attached meeting charts. PAtGtG./bam gg & - 000155 EID080269 '- . . Meeting Attendees: FJ..EC.. FBrreencckhenridge H. E. Hiestand . WR.. HN.. DKanronwellels LSs.. PB.ercCiuvpapl, PPE. R A. J. A. C. BWroingnhett,t, TEFR RR.. ED.. RReiacdh,ardJsaocnk,sonCWLab GG.. LH.. PThaatyteerr,sonJ,acJkascoknsoLnabLab H. P. J. W. STcrhoncehiidmeorw,iczH,askHealslkell 3 = 000156 EID080270 ' .